Details for Patent: 8,361,500

Which drugs does patent 8,361,500 protect, and when does it expire?

Patent 8,361,500 protects VARUBI and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 8,361,500

Title:	Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Abstract:	Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Inventor(s):	Zhihui Qiu, Wing-Kee Philip Cho, Na Zhao, Victor Ming-She Wong
Assignee:	Opko Health Inc
Application Number:	US12/531,966
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Process; Dosage form;

Drugs Protected by US Patent 8,361,500

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes	8,361,500		Y

Foreign Priority and PCT Information for Patent: 8,361,500

PCT Information
PCT Filed	March 20, 2008	PCT Application Number:	PCT/US2008/003653
PCT Publication Date:	October 02, 2008	PCT Publication Number:	WO2008/118331

International Family Members for US Patent 8,361,500

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	065802
Canada	2681465
Chile	2008000819